Head-to-head · WeighScore
Embody vs OrderlyMeds
By GLP-1 ScorecardUpdated
Score comparison
Embody has the higher recorded score — 76.5/100 to 67/100.
Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody is a low-cost injection option, but the modest prepaid savings deserve a close look beside its payment-finality and renewal rules.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Embody | OrderlyMeds |
|---|---|---|
| WeighScore | 76.5/100 | 67/100 |
| Grade | C | C |
| Site position | #52 | #192 |
| Semaglutide | $79/mo (one-month injection; $828 annual prepay equals $69/mo) | $74/mo (starting dose, 2-mo starter plan, new patients only, compounded) |
| Tirzepatide | $129/mo (one-month injection; $1,428 annual prepay equals $119/mo) | $299/mo (compounded) |
| Coverage | State eligibility not fully published; confirm your location | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #52 · C
Strengths
- One-month injection offers at $79 semaglutide and $129 tirzepatide
- Separate monthly, three-, six- and twelve-month price tiers published
- OpenLoop care network and four pharmacy partners publicly named; individual assignment still needs confirmation
What to consider
- Payments are described as final at purchase except provider-initiated medical disqualification, with used services deducted
- Cancel at least 72 hours before renewal; unused prepaid months are not routinely refundable
- Homepage week counts differ from product month labels; confirm supply and charge dates
- Current catalog supports injections; no active oral-gum offer or universal state footprint confirmed
Site position #192 · C
FDAWarning letter issued to OrderlyMeds LLC dba OrderlyMeds in June 2026. See the FDA warning-letter database.
Strengths
- The starter rate and the standing rate are both published, so the step-up is visible before signing up
- No membership fees and no hidden costs, stated as such
- The dose ladder is published: four weeks at 0.25 mg then four weeks at 0.5 mg
- Brand-name routes are priced openly, at retail
What to consider
- The $74 rate is a two-month starter plan billed as $149 up front, and it is open only to patients new to GLP-1 medication; the standing monthly rate is $149
- Tirzepatide has no equivalent standing discount — $299/mo is the ongoing rate
- Brand-name routes are priced at retail: Wegovy $1,839 and Zepbound $1,498
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- FDA issued OrderlyMeds LLC dba OrderlyMeds a warning letter in June 2026; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.